Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD2 | O60906 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 8/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.41 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 4/20 | 0.40 |
| ▸ | PPARA | Q07869 | 4/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.39 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1697074 | 1.00 | SMPD2 (0.48) | SMPD2SIGMAR1KDM4EALDH1A1TDP1 | |
| SCHEMBL29643326 | 0.82 | SIGMAR1 (0.50) | SMPD2SIGMAR1NR4A1NR4A2NR4A3 | |
| SCHEMBL29643341 | 0.82 | SIGMAR1 (0.50) | SMPD2SIGMAR1NR4A1NR4A2NR4A3 | |
| SCHEMBL7366363 | 0.82 | SIGMAR1 (0.50) | SMPD2SIGMAR1NR4A1NR4A2NR4A3 | |
| SCHEMBL7563347 | 0.82 | SMPD2 (0.49) | SMPD2SIGMAR1KDM4EALDH1A1TDP1 | |
| SCHEMBL173511 | 0.82 | SIGMAR1 (0.50) | SMPD2SIGMAR1NR4A1NR4A2NR4A3 | |
| SCHEMBL173510 | 0.82 | SIGMAR1 (0.50) | SMPD2SIGMAR1NR4A1NR4A2NR4A3 | |
| SCHEMBL6113112 | 0.79 | SMPD2 (0.47) | SMPD2SIGMAR1NR4A1NR4A2NR4A3 | |
| SCHEMBL6119288 | 0.79 | SMPD2 (0.47) | SMPD2SIGMAR1NR4A1NR4A2NR4A3 | |
| SCHEMBL6113113 | 0.79 | SMPD2 (0.47) | SMPD2SIGMAR1NR4A1NR4A2NR4A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102325539-A | Amide based glucagon superfamily peptide prodrugs | UNIV INDIANA RES & TECH CORP | 2012-01-18 | — | — | CN | claimed |
| JP-2009529509-A | — | — | 2009-08-20 | — | — | JP | claimed |
| EP-2007791-A2 | MODIFIED MOLECULES WHICH PROMOTE HEMATOPOIESIS | AplaGen GmbH (DE) | 2008-12-31 | — | — | EP | claimed |
| WO-2007101698-A2 | MODIFIED MOLECULES WHICH PROMOTE HEMATOPOIESIS | APLAGEN GMBH (DE) | 2007-09-13 | — | — | WO | claimed |
| CN-108137676-B | gp120 neutralizing antibodies and uses thereof | 美国政府(由卫生和人类服务部的部长所代表) | 2022-03-15 | — | — | CN | disclosed |
| CN-104583233-B | Show the analog of the glucagon of GIP receptor actives | 印第安纳大学研究及科技有限公司 | 2018-10-23 | — | — | CN | disclosed |
| CN-103458920-B | Show the glucagon analogs of GIP receptor active | 印第安那大学科技研究公司 | 2016-07-06 | — | — | CN | disclosed |
| CN-105324125-A | Prodrugs with prolonged action | UNIV INDIANA RES & TECH CORP | 2016-02-10 | — | — | CN | disclosed |
| CN-102958533-B | The medicament that dipeptides connects | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORP. (US) | 2016-01-20 | — | — | CN | disclosed |
| CN-104583233-A | Analogs of glucagon exhibiting GIP receptor activity | UNIV INDIANA RES & TECH CORP | 2015-04-29 | — | — | CN | disclosed |
| CN-104583232-A | Glucagon analogs exhibiting GIP receptor activity | UNIV INDIANA RES & TECH CORP | 2015-04-29 | — | — | CN | disclosed |
| CN-103458920-A | Glucagon analogs exhibiting GIP receptor activity | UNIV INDIANA RES & TECH CORP | 2013-12-18 | — | — | CN | disclosed |
| CN-103179979-A | Amide-based glucagon superfamily peptide prodrugs | UNIV INDIANA RES & TECH CORP | 2013-06-26 | — | — | CN | disclosed |
| CN-102958533-A | Dipeptide linked medicinal agents | UNIV INDIANA RES & TECH CORP | 2013-03-06 | — | — | CN | disclosed |
| CN-102325539-A | Amide based glucagon superfamily peptide prodrugs | UNIV INDIANA RES & TECH CORP | 2012-01-18 | — | — | CN | disclosed |
| CN-102300580-A | Dipeptide linked medicinal agents | — | 2011-12-28 | — | — | CN | disclosed |
| US-20090281278-A1 | MODIFIED MOLECULES WHICH PROMOTE HEMATOPOIESIS | APLAGEN GMBH (DE) | 2009-11-12 | — | — | US | disclosed |
| EP-2007791-A2 | MODIFIED MOLECULES WHICH PROMOTE HEMATOPOIESIS | AplaGen GmbH (DE) | 2008-12-31 | — | — | EP | disclosed |
| WO-2007101698-A2 | MODIFIED MOLECULES WHICH PROMOTE HEMATOPOIESIS | APLAGEN GMBH (DE) | 2007-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281278-A1 | MODIFIED MOLECULES WHICH PROMOTE HEMATOPOIESIS | EPOR, MPL, THPO | SMPD2 1511/4885SIGMAR1 3476/4885KDM4E 2046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.